DSpace at RU >

Search Results

Results 1-50 of 210.

Item hits:

Full Text	Issue Date	Title	Author(s)
	2013	Van vaten, bloeddruk en vetten	Stalenhoef, A.F.H.; Lenders, J.W.M.
	2011	Should preclinical vascular abnormalities be measured in asymptomatic adults to improve cardiovascular risk stratification?	Graaf, J. de; Holewijn, S.; Stalenhoef, A.F.H.; Sniderman, A.D.
	2011	Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias: ApoB dyslipoproteinemias in a Dutch population-based study	Holewijn, S.; Sniderman, A.D.; Heijer, M. den; Swinkels, D.W.; Stalenhoef, A.F.H.; Graaf, J. de
	2011	Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel-like factor 2	Tits, L.J.H. van; Stienstra, R.; Lent, P.L.E.M. van; Netea, M.G.; Joosten, L.A.B.; Stalenhoef, A.F.H.
	2011	Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1beta transcription in human adipose tissue	Koenen, T.B.; Stienstra, R.; Tits, L.J.H. van; Graaf, J. de; Stalenhoef, A.F.H.; Joosten, L.A.B.; Tack, C.J.J.; Netea, M.G.
	2011	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)	Reiner, Z.; Catapano, A.L.; Backer, G. de; Graham, I.; Taskinen, M.R.; Wiklund, O.; Agewall, S.; Alegria, E.; Chapman, M.J.; Durrington, P.; Erdine, S.; Halcox, J.; Hobbs, R.; Kjekshus, J.; Filardi, P.P.; Riccardi, G.; Storey, R.F.; Wood, D.; Bax, J.; Vahanian, A.; Auricchio, A.; Baumgartner, H.; Ceconi, C.; Dean, V.; Deaton, C.; Fagard, R.; Filippatos, G.; Funck-Brentano, C.; Hasdai, D.; Hoes, A.; Kearney, P.; Knuuti, J.; Kolh, P.; McDonagh, T.; Moulin, C.; Poldermans, D.; Popescu, B.A.; Sechtem, U.; Sirnes, P.A.; Tendera, M.; Torbicki, A.; Vardas, P.; Widimsky, P.; Windecker, S.; Berkenboom, G.; Graaf, J. de; Descamps, O.; Gotcheva, N.; Griffith, K.; Guida, G.F.; Gulec, S.; Henkin, Y.; Huber, K.; Kesaniemi, Y.A.; Lekakis, J.; Manolis, A.J.; Marques-Vidal, P.; Masana, L.; McMurray, J.; Mendes, M.; Pagava, Z.; Pedersen, T.; Prescott, E.; Rato, Q.; Rosano, G.; Sans, S.; Stalenhoef, A.F.H.; Tokgozoglu, L.; Viigimaa, M.; Wittekoek, M.E.; Zamorano, J.L.
	2011	The inflammasome and caspase-1 activation: a new mechanism underlying increased inflammatory activity in human visceral adipose tissue	Koenen, T.B.; Stienstra, R.; Tits, L.J. van; Joosten, L.A.B.; Velzen, J.F. van; Hijmans, A.G.M.; Pol, J.A.; Vliet, J.A. van der; Netea, M.G.; Tack, C.J.J.; Stalenhoef, A.F.H.; Graaf, J. de
	2010	Running on age in a 15-km road run: minor influence of age on performance.	Celie, F.; Faes, M.C.; Hopman, M.T.E.; Stalenhoef, A.F.H.; Olde Rikkert, M.G.M.
	2010	Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe.	Thompson, G.R.; Catapano, A.; Saheb, S.; Atassi-Dumont, M.; Barbir, M.; Eriksson, M.; Paulweber, B.; Sijbrands, E.; Stalenhoef, A.F.H.; Parhofer, K.G.
	2010	Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.	Brouwers, M.C.; Graaf, J. de; Greevenbroek, M.M. van; Schaper, N.; Stehouwer, C.D.A.; Stalenhoef, A.F.H.
	2010	Non-invasive measurements of atherosclerosis (NIMA): current evidence and future perspectives.	Holewijn, S.; Heijer, M. den; Stalenhoef, A.F.H.; Graaf, J. de
	2010	Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.	Himbergen, T. van; Otokozawa, S.; Matthan, N.R.; Schaefer, E.J.; Buchsbaum, A.; Ai, M.; Tits, L.J.H. van; Graaf, J. de; Stalenhoef, A.F.H.
	2010	Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies.	Vergeer, M.; Zhou, R.; Bots, M.L.; Duivenvoorden, R.; Koglin, J.; Akdim, F.; Mitchel, Y.B.; Huijgen, R.; Sapre, A.; Groot, E. de; Sijbrands, E.J.; Pasternak, R.C.; Gagne, C.; Marais, A.D.; Ballantyne, C.M.; Isaacsohn, J.L.; Stalenhoef, A.F.H.; Kastelein, J.J.
	2010	Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk.	Holewijn, S.; Heijer, M. den; Swinkels, D.W.; Stalenhoef, A.F.H.; Graaf, J. de
	2010	Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.	Pijlman, A.H.; Huijgen, R.; Verhagen, S.N.; Imholz, B.P.; Liem, A.H.; Kastelein, J.J.; Abbink, E.J.; Stalenhoef, A.F.H.; Visseren, F.L.
	2010	Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis.	Joosten, L.A.B.; Netea, M.G.; Mylona, E.; Koenders, M.I.; Malireddi, R.K.; Oosting, M.; Stienstra, R.; Veerdonk, F.L. van de; Stalenhoef, A.F.H.; Giamarellos-Bourboulis, E.J.; Kanneganti, T.D.; Meer, J.W.M. van der
	2010	Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials.	Dogan, S.; Duivenvoorden, R.; Grobbee, D.E.; Kastelein, J.J.; Shear, C.L.; Evans, G.W.; Visseren, F.L.; Bots, M.L.; Stalenhoef, A.F.H.
	2010	Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.	Huijgen, R.; Abbink, E.J.; Bruckert, E.; Stalenhoef, A.F.H.; Imholz, B.P.; Durrington, P.N.; Trip, M.D.; Eriksson, M.; Visseren, F.L.; Schaefer, J.R.; Kastelein, J.J.
	2010	Impact of waist circumference versus adiponectin level on subclinical atherosclerosis: a cross-sectional analysis in a sample from the general population.	Holewijn, S.; Heijer, M. den; Tits, L.J.H. van; Swinkels, D.W.; Stalenhoef, A.F.H.; Graaf, J. de
	2009	Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.	Himbergen, T. van; Otokozawa, S.; Matthan, N.R.; Schaefer, E.J.; Buchsbaum, A.; Ai, M.; Tits, L.J.H. van; Graaf, J. de; Stalenhoef, A.F.H.
	2009	The benefit of statins in non-cardiac vascular surgery patients.	Stalenhoef, A.F.H.
	2009	Cardiac complication after experimental human malaria infection: a case report.	Nieman, A.E.; Mast, Q. de; Roestenberg, M.; Wiersma, J.; Pop, G.A.M.; Stalenhoef, A.F.H.; Druilhe, P.; Sauerwein, R.W.; Ven, A.J.A.M. van der
	2009	Circulating lipoproteins are a crucial component of host defense against invasive Salmonella typhimurium infection.	Netea, M.G.; Joosten, L.A.B.; Keuter, M.; Wagener, F.A.D.T.G.; Stalenhoef, A.F.H.; Meer, J.W.M. van der; Kullberg, B.J.
	2009	Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn?	Avis, H.J.; Hutten, B.A.; Twickler, T.B.; Kastelein, J.J.; Post, J.A. van der; Stalenhoef, A.F.H.; Vissers, M.N.
	2009	Severity of iron overload of proband determines serum ferritin levels in families with HFE-related hemochromatosis: the HEmochromatosis FAmily Study.	Jacobs, E.M.G.; Hendriks, J.C.M.; Deursen, C.T. van; Kreeftenberg, H.G.; Vries, R.A. de; Marx, J.J.M.; Stalenhoef, A.F.H.; Verbeek, A.L.M.; Swinkels, D.W.
	2009	Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study.	Heintjes, E.M.; Penning-van Beest, F.J.A.; Johansson, S.; Stalenhoef, A.F.H.; Herings, R.M.C.
	2009	The expression of type III hyperlipoproteinemia: involvement of lipolysis genes.	Henneman, P.; Sman-de Beer, F. van der; Moghaddam, P.H.; Huijts, P.; Stalenhoef, A.F.H.; Kastelein, J.J.; Duijn, C.M. van; Havekes, L.M.; Frants, R.R.; Dijk, K.W. van; Smelt, A.H.
	2009	Brachial artery diameter is related to cardiovascular risk factors and intima-media thickness.	Holewijn, S.; Heijer, M. den; Swinkels, D.W.; Stalenhoef, A.F.H.; Graaf, J. de
	2009	Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients.	Koenen, T.B.; Tack, C.J.J.; Kroese, J.M.; Hermus, A.R.M.M.; Sweep, C.G.J.; Laak, J.A.W.M. van der; Stalenhoef, A.F.H.; Graaf, J. de; Tits, L.J.H. van; Stienstra, R.
	2009	The metabolic syndrome and its traits as risk factors for subclinical atherosclerosis.	Holewijn, S.; Heijer, M. den; Swinkels, D.W.; Stalenhoef, A.F.H.; Graaf, J. de
	2009	Evaluation of PubMed filters used for evidence-based searching: validation using relative recall.	Hoogendam, A.; Vries Robbe, P.F. de; Stalenhoef, A.F.H.; Overbeke, A.J.P.M.
	2009	Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.	Popa, C.; Tits, L.J.H. van; Barrera Rico, P.; Lemmers, H.L.M.; Hoogen, F.H.J. van den; Riel, P.L.C.M. van; Radstake, T.R.D.J.; Netea, M.G.; Roest, M.; Stalenhoef, A.F.H.
	2009	Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.	Popa, C.; Netea, M.G.; Graaf, J. de; Hoogen, F.H.J. van den; Radstake, T.R.D.J.; Toenhake-Dijkstra, H.I.; Riel, P.L.C.M. van; Meer, J.W.M. van der; Stalenhoef, A.F.H.; Barrera, P.
	2008	The Netherlands Journal of Medicine: seven years editorial office in Nijmegen, entering a new era.	Stalenhoef, A.F.H.
	2008	Chylomicrons in disease: a renaissance in lipidology International Symposium of Chylomicrons in Disease (ISCD), Lake Louise, Alberta, Canada, March 6th-8th, 2008.	Stalenhoef, A.F.H.; Watts, G.F.
	2008	Oxidized low-density lipoprotein is not equal to oxidative stress.	Tits, L.J.H. van; Stalenhoef, A.F.H.
	2008	Cardiovasculaire preventie bij 80-plussers is nuttig	Stalenhoef, A.F.H.
	2008	[No reason to start treatment with statins in patients with moderate to severe heart failure]	Stalenhoef, A.F.H.
	2008	Paraoxonase (PON1) is associated with familial combined hyperlipidemia.	Himbergen, TM van; Tits, L.J.H. van; Avest, E. ter; Roest, M.; Voorbij, H.A.; Graaf, J. de; Stalenhoef, A.F.H.
	2008	Silent exonic mutations in the low-density lipoprotein receptor gene that cause familial hypercholesterolemia by affecting mRNA splicing.	Defesche, J.C.; Schuurman, E.J.M.; Klaaijsen, L.N.; Khoo, K.L.; Wiegman, A.; Stalenhoef, A.F.H.
	2008	Effects of ubiquinone (coenzyme Q10) on myopathy in statin users.	Schaars, C.F.; Stalenhoef, A.F.H.
	2008	Cholesterol in end-stage renal disease: the good, the bad or the ugly?	Diepeveen, S.H.A.; Wetzels, J.F.M.; Bilo, H.J.; Tits, L.J.H. van; Stalenhoef, A.F.H.
	2008	Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL.	Stalenhoef, A.F.H.; Graaf, J. de
	2008	JTT-705: is there still future for a CETP inhibitor after torcetrapib?	Rennings, A.J.M.; Stalenhoef, A.F.H.
	2008	Adiponectin multimer distribution in patients with familial combined hyperlipidemia.	Koenen, T.B.; Tits, L.J.H. van; Holewijn, S.; Lemmers, H.L.M.; Heijer, M. den; Stalenhoef, A.F.H.; Graaf, J. de
	2008	Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women.	Himbergen, TM van; Schouw, Y.T. van der; Voorbij, H.A.; Tits, L.J.H. van; Stalenhoef, A.F.H.; Peeters, P.H.; Roest, M.
	2008	Answers to questions posed during daily patient care are more likely to be answered by UpToDate than PubMed.	Hoogendam, A.; Stalenhoef, A.F.H.; Robbe, P.F.; Overbeke, A.J.P.M.
	2008	LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results.	Heintjes, E.M.; Hirsch, M.W.; Linden, MW van der; O'Donnell, J.C.; Stalenhoef, A.F.H.; Herings, R.M.C.
	2008	Analysis of queries sent to PubMed at the point of care : observation of search behaviour in a medical teaching hospital	Hoogendam, A.; Stalenhoef, A.F.H.; Robbe, P.F.; Overbeke, A.J.P.M.
	2008	Parabolic relationship between plasma triacylglycerols and LDL-cholesterol in familial combined hyperlipidaemia: the multiple-type hyperlipidaemia explained?	Brouwers, M.C.; Graaf, J. de; Greevenbroek, MM van; Georgieva, A.M.; Kallen, CJ van der; Avest, E. ter; Stehouwer, C.D.A.; Stalenhoef, A.F.H.; Bruin, T.W.A. de

1 2 3 4 5 next